August 24, 2018

Stanton A. Glantz, PhD

Two new peer reviewed papers discuss how PMI's own data shows they are as dangerous, maybe worse, than cigarettes

Tobacco Control just published two peer reviewed papers based on close reads of the raw data buried in Philip Morris International's application to FDA to sell IQOS as a reduced risk product.

As the title " PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes" indicates, PMI's own data shows that the measures of health impact that IQOS has are not statistically different from conventional cigarettes.  (I wrote a piece on The Conversation summarizing these results in simple English a few months ago.)

The second paper, "Possible hepatotoxicity of IQOS," shows in animal and human studies that IQOS change liver function in way that cigarettes do not, which suggests that long-term use of IQOS could damage livers.

Again, both these papers are based in PMI's own data.

PMI is aggressively promoting IQOS all over the world as safer, likely hoping that no one will dig through the actual scientific data, which contradicts PMI's claims.

Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.